{
    "data": {
        "idp": {
            "IDP_Unq_ID": "IDP001",
            "Description": "Please add description here....",
            "CreatedBy": null,
            "UpdatedBy": null,
            "CreatedAt": "2024-10-08T17:37:00Z",
            "UpdatedAt": "2024-10-08T19:20:00Z",
            "Status": "in_progress",
            "CurrentVersion": "2.0",
            "IDP_Name": "LungStudy"
        },
        "studies": [
            {
                "StudyNumber": "ML21768",
                "StudyPhase": "Phase III",
                "StudyIndication": "Colorectal cancer",
                "StudyScientificArea": "Oncology | Gastroenterology",
                "Study_Unq_ID": "00001bd9-da12-4f55-bdb0-a95a392a7640",
                "StudyID": "http://clinical.roche.com/study/ML21768",
                "StudyCITFlag": "N",
                "StudyThemeMolecule": "Avastin",
                "StudyScientificTitle": "Randomized 3arm PH III trial on induction of FOLFOX or XELOX both with beva for 24 weeks followed by a maintenance treatment with beva and 5-fluorouracil/folinic acid or cape vs. beva alone vs. no maintenance treatment and reinduction in case of progr. for first-line treatment of pat. with met.crc", 
                "StudyType": "Interventional",
                "StudyStatus": "Clinical Closure",
                "StudySource": "MDMS",
                "StudyNonRocheNumber": "",
                "StudyAcronym": "MAINTENANCE",
                "StudyRocheNumber": "RO4876646",
                "StudyPlanneEnrollment": 840,
                "StudyActuaeEnrollment": 852,
                "StudyAccountableRoceParty": "LMA",
                "StudyExecutingParty": "Collaborative Group",
                "StudyBlinding": "Open-label",
                "StudyRandomization": "Randomized",
                "StudyPopulation": "Patients",
                "StudyComparison": "Active Controlled",
                "StudyTherapySetting": "",
                "StudyLineTherapy": "",
                "StudyNCTNumber": "NCT00973609",
                "StudyEudraCTNumber": "2008-007974-39",
                "StudyShortTitle": "Optimierte Sequenztherapie",
                "StudyThemeNumber": "9578",
                "StudySponsorType": "",
                "StudyLeader": "",
                "StudyCreateDATE": "12/4/2015",
                "StudyCreateUser": "",
                "StudyDataSource": null,
                "StudyNosOfSubject": null,
                "StudyHasImaging": 0,
                "StudyHasCDSE": 0,
                "StudyHasOMICS": 0,
                "StudyNosOfVisits": null,
                "StudyNosOfAcquistions": null,
                "StudyNosOfFiles": null,
                "StudyFinalDATEePlanned": "2024-10-08",
                "StudyFinalDATEeActual": "2024-10-08",
                "StudyPCDPlanned": "2024-10-08",
                "StudyPCDActual": "2024-10-08",
                "StudyImagingModality": "",
                "CreatedBy": "",
                "UpdatedBy": "",
                "CreatedAt": "2024-10-08T17:37:00Z",
                "UpdatedAt": "2024-10-08T17:37:00Z",
                "SourceType": "GIP, RWD",
                "Is_Active": 1
            },
            {
                "StudyNumber": "BP15387",
                "StudyPhase": "Phase I",
                "StudyIndication": "Not specified",
                "StudyScientificArea": "",
                "Study_Unq_ID": "00070b13-5b2e-4ed6-8ad2-5325f4496a26",
                "StudyID": "http://clinical.roche.com/study/BP15387",              
                "StudyCITFlag": "N",
                "StudyThemeMolecule": "",
                "StudyScientificTitle": "An ascending dose study of the tolerability, safety, pharmacodynamics, pharmacokinetics of an IV infusion of endothelin antagonist Ro 61-1790 in healthy, male voluteers.", 
                "StudyType": "Interventional",
                "StudyStatus": "Clinical Closure",
                "StudySource": "AIMS",
                "StudyNonRocheNumber": "",
                "StudyAcronym": "",
                "StudyRocheNumber": "",
                "StudyPlanneEnrollment": 0,
                "StudyActuaeEnrollment": 49,
                "StudyAccountableRoceParty": "PD",
                "StudyExecutingParty": "",
                "StudyBlinding": "Double-blind",
                "StudyRandomization": "",
                "StudyPopulation": "",
                "StudyComparison": "Placebo Controlled",
                "StudyTherapySetting": "",
                "StudyLineTherapy": "",
                "StudyNCTNumber": "",
                "StudyEudraCTNumber": "",
                "StudyShortTitle": "EIM STUDY: PK/PD ASCEND. DOSE",
                "StudyThemeNumber": "3179",
                "StudySponsorType": "",
                "StudyLeader": "",
                "StudyCreateDATE": "",
                "StudyCreateUser": "",
                "StudyDataSource": null,
                "StudyNosOfSubject": null,
                "StudyHasImaging": 0,
                "StudyHasCDSE": 0,
                "StudyHasOMICS": 0,
                "StudyNosOfVisits": null,
                "StudyNosOfAcquistions": null,
                "StudyNosOfFiles": null,
                "StudyFinalDATEePlanned": "2024-10-08",
                "StudyFinalDATEeActual": "2024-10-08",
                "StudyPCDPlanned": "2024-10-08",
                "StudyPCDActual": "2024-10-08",
                "StudyImagingModality": "",
                "CreatedBy": "",
                "UpdatedBy": "",
                "CreatedAt": "2024-10-08T17:37:00Z",
                "UpdatedAt": "2024-10-08T17:37:00Z",
                "SourceType": "GIP, RWD",
                "Is_Active": 1
            }
        ]
    }
}